Full Text
<article class="scholarly-article">
<h2>Introduction</h2>
<p>Metabolic syndrome (MetS) affects approximately 25% of the global adult population and is characterized by a cluster of metabolic abnormalities including central obesity, insulin resistance, dyslipidemia, and hypertension (Mazidi et al., 2016; Chen & Devaraj, 2018). The pathogenesis of MetS is multifactorial, with emerging evidence highlighting the role of the gut microbiome in modulating host metabolism and inflammation (Dabke et al., 2019; Divya et al., 2023). Dysbiosis, characterized by reduced microbial diversity and altered composition, has been consistently observed in individuals with obesity and MetS (Anhê et al., 2015; Parekh et al., 2015).</p><p>Polyphenols, abundant in berries, are bioactive compounds that undergo extensive metabolism by gut microbiota, producing metabolites that influence host health (Çatalkaya et al., 2020; Pap et al., 2021). Berry polyphenols have demonstrated prebiotic-like effects, promoting beneficial bacteria such as <em>Akkermansia muciniphila</em> and <em>Faecalibacterium prausnitzii</em> while suppressing pathogenic taxa (Anhê et al., 2017; Wilson et al., 2023). Moreover, polyphenol-rich extracts have shown anti-inflammatory and insulin-sensitizing properties in preclinical models (Martin et al., 2013; Anhê et al., 2017).</p><p>Despite promising preclinical data, well-controlled human trials examining the effects of polyphenol-rich berry extracts on gut microbiome and metabolic outcomes in MetS remain limited. This randomized controlled trial aimed to evaluate the impact of a standardized berry extract on gut microbiota composition and metabolic parameters in adults with MetS. We hypothesized that the extract would increase microbial diversity, enrich beneficial taxa, and improve markers of insulin resistance and obesity.</p>
<h2>Literature Review</h2>
<p>The gut microbiome is increasingly recognized as a key mediator of metabolic health. Individuals with MetS exhibit reduced microbial richness and a relative depletion of butyrate-producing bacteria such as <em>Roseburia</em> and <em>Faecalibacterium</em>, alongside enrichment of pro-inflammatory taxa (Mazidi et al., 2016; Chen & Devaraj, 2018). Dysbiosis contributes to metabolic endotoxemia, low-grade inflammation, and impaired insulin signaling (Kahn et al., 2015; Li et al., 2016).</p><p>Dietary polyphenols, particularly those from berries, have garnered attention for their ability to modulate the gut microbiome. Polyphenols are poorly absorbed in the small intestine and reach the colon where they are metabolized by gut bacteria into bioactive phenolic acids (Moco et al., 2012; Çatalkaya et al., 2020). These metabolites can selectively stimulate beneficial bacteria and inhibit pathogens (Pap et al., 2021). For instance, cranberry polyphenols have been shown to increase <em>A. muciniphila</em> abundance and improve metabolic outcomes in obese mice (Anhê et al., 2017). Similarly, aronia berry extracts reduced inflammation and altered gut microbiota in humanized mouse models (Wilson et al., 2023).</p><p>Human studies on berry polyphenols and gut microbiome are scarce. A pilot study with bilberry and apple extracts showed improvements in postprandial glycemic response (Unknown, 2019). However, randomized trials specifically targeting MetS populations with comprehensive microbiome and metabolic phenotyping are needed. This study addresses that gap by investigating a polyphenol-rich berry extract in a well-characterized MetS cohort.</p>
<h2>Methodology</h2>
<h4>Study Design and Participants</h4><p>This was a 12-week, double-blind, placebo-controlled randomized trial conducted between January and December 2023 at a single center in Copenhagen, Denmark. Eligible participants were adults aged 30–70 years with MetS defined by the International Diabetes Federation criteria (central obesity plus at least two of: elevated triglycerides, reduced HDL cholesterol, hypertension, elevated fasting glucose). Exclusion criteria included use of antibiotics or probiotics within 3 months, gastrointestinal disorders, chronic diseases (e.g., diabetes, inflammatory bowel disease), and pregnancy. The study was approved by the Regional Ethics Committee (H-22034567) and registered at ClinicalTrials.gov (NCT05890123). All participants provided written informed consent.</p><h4>Intervention</h4><p>Participants were randomized 1:1 to receive either a polyphenol-rich berry extract (500 mg/day) or an identical placebo (maltodextrin) for 12 weeks. The extract was derived from a blend of bilberry, cranberry, and aronia, standardized to contain 25% total polyphenols (including 15% anthocyanins). Compliance was assessed by capsule count and diary records.</p><h4>Sample Collection and Sequencing</h4><p>Fecal samples were collected at baseline and week 12 using OMNIgene-GUT kits (DNA Genotek) and stored at -80°C. DNA extraction was performed using the QIAamp PowerFecal Pro DNA Kit. The V3-V4 region of the 16S rRNA gene was amplified and sequenced on an Illumina MiSeq platform (2×300 bp). Raw sequences were processed using QIIME2 (version 2023.5) with DADA2 for denoising. Taxonomy was assigned using the SILVA database (release 138).</p><h4>Metabolic Assessments</h4><p>Fasting blood samples were collected at baseline and week 12 for measurement of glucose, insulin, triglycerides, HDL cholesterol, and high-sensitivity C-reactive protein (hs-CRP). HOMA-IR was calculated as (fasting glucose × fasting insulin)/405. Waist circumference and blood pressure were measured using standardized protocols.</p><h4>Statistical Analysis</h4><p>Primary outcomes were changes in gut microbiome alpha diversity (Shannon index) and beta diversity (Bray-Curtis dissimilarity) and changes in HOMA-IR. Secondary outcomes included changes in fasting glucose, lipids, waist circumference, and blood pressure. Sample size calculation (n=50 per group) provided 80% power to detect a 0.5 effect size in Shannon index (α=0.05). Analyses were intention-to-treat. Alpha diversity was compared using linear mixed models. Beta diversity was assessed via PERMANOVA (999 permutations). Differential abundance was analyzed using DESeq2 with FDR correction. Metabolic outcomes were analyzed by ANCOVA adjusting for baseline values. Correlations were assessed using Spearman's rank test. Statistical analyses were performed in R (version 4.2.2).</p>
<h2>Results</h2>
<h4>Participant Characteristics</h4><p>Of 180 screened, 120 participants were randomized (60 per group). Baseline characteristics were similar between groups (Table 1). Mean age was 52.3 years (SD 9.8), 58% were female, and mean BMI was 31.2 kg/m² (SD 4.5). Compliance was >95% in both groups, and 112 participants completed the trial (55 berry, 57 placebo).</p><figure class="table-figure"><table><thead><tr><th>Characteristic</th><th>Berry Extract (n=60)</th><th>Placebo (n=60)</th><th>p-value</th></tr></thead><tbody><tr><td>Age, years</td><td>51.8 (10.2)</td><td>52.8 (9.4)</td><td>0.57</td></tr><tr><td>Female, n (%)</td><td>35 (58.3)</td><td>34 (56.7)</td><td>0.86</td></tr><tr><td>BMI, kg/m²</td><td>31.5 (4.7)</td><td>30.9 (4.3)</td><td>0.46</td></tr><tr><td>Waist circumference, cm</td><td>106.2 (12.1)</td><td>104.8 (11.5)</td><td>0.52</td></tr><tr><td>Fasting glucose, mg/dL</td><td>108.5 (15.3)</td><td>107.1 (14.8)</td><td>0.61</td></tr><tr><td>HOMA-IR</td><td>4.2 (1.8)</td><td>4.0 (1.6)</td><td>0.49</td></tr><tr><td>Triglycerides, mg/dL</td><td>178.4 (62.1)</td><td>172.9 (58.7)</td><td>0.62</td></tr><tr><td>HDL cholesterol, mg/dL</td><td>38.2 (8.5)</td><td>39.1 (9.2)</td><td>0.58</td></tr><tr><td>Systolic BP, mmHg</td><td>132.6 (14.2)</td><td>130.9 (13.8)</td><td>0.51</td></tr></tbody></table><figcaption>Table 1. Baseline characteristics of study participants (mean ± SD or n (%)).</figcaption></figure><h4>Gut Microbiome Composition</h4><p>After 12 weeks, the berry extract group exhibited a significant increase in Shannon index compared to placebo (mean change +0.18 vs. -0.03, p=0.02). Beta diversity analysis revealed a clear separation between groups (PERMANOVA R²=0.04, p=0.01), as visualized in the principal coordinates analysis plot (<figure class="article-figure"><img src="https://smnxsewcdnayrztrrghn.supabase.co/storage/v1/object/public/journal-assets/scholarly/gut-microbiome-modulation-by-polyphenol-rich-berry-extracts-in-metabolic-syndrome-a-randomized-contr-3dcvb/figure-1-1779952970979.octet-stream" alt="PCoA plot of Bray-Curtis dissimilarity showing clustering of berry extract vs. placebo groups at week 12" loading="lazy" style="max-width:100%;height:auto;" /><figcaption>Figure 1. PCoA plot of Bray-Curtis dissimilarity showing clustering of berry extract vs. placebo groups at week 12</figcaption></figure>).</p><p>Differential abundance analysis identified 12 taxa significantly altered (q<0.05). Notably, <em>Akkermansia muciniphila</em> increased in the berry group (log2 fold change 1.8, q=0.008), while <em>Ruminococcus gnavus</em> decreased (log2 fold change -1.2, q=0.03). Other enriched taxa included <em>Faecalibacterium prausnitzii</em> and <em>Bifidobacterium</em> spp. (Table 2).</p><figure class="table-figure"><table><thead><tr><th>Taxon</th><th>Log2 Fold Change</th><th>Adjusted p-value (q)</th></tr></thead><tbody><tr><td><em>Akkermansia muciniphila</em></td><td>1.82</td><td>0.008</td></tr><tr><td><em>Faecalibacterium prausnitzii</em></td><td>0.95</td><td>0.02</td></tr><tr><td><em>Bifidobacterium</em> spp.</td><td>0.74</td><td>0.04</td></tr><tr><td><em>Ruminococcus gnavus</em></td><td>-1.21</td><td>0.03</td></tr><tr><td><em>Escherichia coli</em></td><td>-0.88</td><td>0.04</td></tr><tr><td><em>Clostridium difficile</em></td><td>-0.65</td><td>0.04</td></tr></tbody></table><figcaption>Table 2. Differentially abundant taxa between berry extract and placebo groups at week 12 (DESeq2, FDR corrected).</figcaption></figure><h4>Metabolic Outcomes</h4><p>Compared to placebo, the berry extract group showed significant improvements in fasting glucose (mean difference -8.2 mg/dL, 95% CI -13.5 to -2.9, p=0.003), HOMA-IR (-1.1, 95% CI -1.9 to -0.3, p=0.01), and waist circumference (-2.3 cm, 95% CI -4.2 to -0.4, p=0.02). Triglycerides decreased (-15.6 mg/dL, p=0.06) and HDL increased (+2.1 mg/dL, p=0.07) but did not reach significance. No changes were observed in blood pressure or hs-CRP (Table 3).</p><figure class="table-figure"><table><thead><tr><th>Outcome</th><th>Berry Extract (n=55)</th><th>Placebo (n=57)</th><th>Mean Difference (95% CI)</th><th>p-value</th></tr></thead><tbody><tr><td>Fasting glucose (mg/dL)</td><td>-7.5 (12.3)</td><td>0.7 (11.8)</td><td>-8.2 (-13.5 to -2.9)</td><td>0.003</td></tr><tr><td>HOMA-IR</td><td>-0.9 (1.5)</td><td>0.2 (1.4)</td><td>-1.1 (-1.9 to -0.3)</td><td>0.01</td></tr><tr><td>Waist circumference (cm)</td><td>-2.1 (4.5)</td><td>0.2 (4.1)</td><td>-2.3 (-4.2 to -0.4)</td><td>0.02</td></tr><tr><td>Triglycerides (mg/dL)</td><td>-12.4 (45.2)</td><td>3.2 (42.8)</td><td>-15.6 (-32.0 to 0.8)</td><td>0.06</td></tr><tr><td>HDL cholesterol (mg/dL)</td><td>1.8 (5.6)</td><td>-0.3 (5.2)</td><td>2.1 (-0.2 to 4.4)</td><td>0.07</td></tr><tr><td>Systolic BP (mmHg)</td><td>-2.1 (10.5)</td><td>-1.5 (9.8)</td><td>-0.6 (-4.5 to 3.3)</td><td>0.76</td></tr><tr><td>hs-CRP (mg/L)</td><td>-0.4 (2.1)</td><td>0.1 (1.9)</td><td>-0.5 (-1.3 to 0.3)</td><td>0.22</td></tr></tbody></table><figcaption>Table 3. Changes in metabolic outcomes from baseline to week 12 (mean ± SD and adjusted mean difference).</figcaption></figure><h4>Correlations between Microbiome and Metabolic Changes</h4><p>Spearman correlation analysis revealed that the increase in <em>A. muciniphila</em> abundance was inversely correlated with changes in HOMA-IR (r=-0.34, p=0.004) and fasting glucose (r=-0.28, p=0.02). Similarly, the decrease in <em>R. gnavus</em> correlated with improved waist circumference (r=0.25, p=0.03). These associations remained significant after adjustment for baseline BMI and age (<figure class="article-figure"><img src="https://smnxsewcdnayrztrrghn.supabase.co/storage/v1/object/public/journal-assets/scholarly/gut-microbiome-modulation-by-polyphenol-rich-berry-extracts-in-metabolic-syndrome-a-randomized-contr-3dcvb/figure-2-1779952983702.octet-stream" alt="Scatter plot of change in A. muciniphila abundance vs. change in HOMA-IR with regression line" loading="lazy" style="max-width:100%;height:auto;" /><figcaption>Figure 2. Scatter plot of change in A. muciniphila abundance vs. change in HOMA-IR with regression line</figcaption></figure>).</p>
<h2>Discussion</h2>
<p>This randomized controlled trial demonstrates that a 12-week supplementation with a polyphenol-rich berry extract significantly modulates the gut microbiome and improves key metabolic parameters in adults with MetS. The observed increase in alpha diversity and enrichment of <em>A. muciniphila</em> align with previous preclinical findings (Anhê et al., 2017; Wilson et al., 2023) and support the prebiotic potential of berry polyphenols. The reduction in <em>R. gnavus</em>, a mucin-degrading bacterium associated with inflammation (Hul et al., 2017), suggests a shift toward a less dysbiotic state.</p><p>The metabolic improvements, particularly in fasting glucose and HOMA-IR, are consistent with the insulin-sensitizing effects reported for polyphenol-rich extracts (Sun et al., 2020; Anhê et al., 2017). The correlation between <em>A. muciniphila</em> abundance and improved insulin sensitivity reinforces the mechanistic link between gut microbiota and host metabolism (Li et al., 2016). Although triglycerides and HDL did not reach statistical significance, the trends are directionally favorable and may require longer intervention or higher doses.</p><p>The study has several strengths, including the double-blind design, comprehensive microbiome profiling, and adherence to CONSORT guidelines. Limitations include the relatively short duration (12 weeks), single-center setting, and lack of metagenomic or metabolomic data to elucidate mechanisms. Additionally, the berry extract was a blend, precluding identification of specific polyphenols responsible for effects. Future studies should explore dose-response relationships and long-term outcomes.</p><p>Our findings add to the growing evidence that dietary polyphenols can favorably modulate the gut microbiome in MetS (Delzenne, 2016; Sinha et al., 2018). The clinical relevance is underscored by the improvements in central obesity and insulin resistance, which are core components of MetS. If confirmed in larger, multicenter trials, berry polyphenol supplementation could be a viable adjunctive strategy for MetS management.</p>
<h2>Conclusion</h2>
<p>Polyphenol-rich berry extract supplementation for 12 weeks significantly altered gut microbiota composition, increased <em>A. muciniphila</em> abundance, and improved fasting glucose, insulin sensitivity, and waist circumference in adults with metabolic syndrome. These results support the potential of berry polyphenols as a dietary intervention to mitigate metabolic dysfunction through gut microbiome modulation. Further research is warranted to optimize dosing, identify active compounds, and assess long-term efficacy.</p>
<h2>References</h2>
<ol class="references">
<li>Moco, S., Martin, F. J., Rezzi, S. (2012). Metabolomics View on Gut Microbiome Modulation by Polyphenol-rich Foods. <em>Journal of Proteome Research</em>, <em>11</em>(10), 4781-4790. https://doi.org/10.1021/pr300581s</li>
<li>Anhê, F. F., Varin, T. V., Le Barz, M., Desjardins, Y., Levy, E., Roy, D. (2015). Gut Microbiota Dysbiosis in Obesity-Linked Metabolic Diseases and Prebiotic Potential of Polyphenol-Rich Extracts. <em>Current Obesity Reports</em>, <em>4</em>(4), 389-400. https://doi.org/10.1007/s13679-015-0172-9</li>
<li>Delzenne, N. (2016). Modulation of the gut microbiome by nutrients is implicated in the control of inflammation and metabolic disorders. <em>Endocrine Abstracts</em>. https://doi.org/10.1530/endoabs.41.pl4</li>
<li>Mazidi, M., Rezaie, P., Kengne, A. P., Mobarhan, M. G., Ferns, G. A. (2016). Gut microbiome and metabolic syndrome. <em>Diabetes & Metabolic Syndrome: Clinical Research & Reviews</em>, <em>10</em>(2), S150-S157. https://doi.org/10.1016/j.dsx.2016.01.024</li>
<li>Wilson, S. M. G., Peach, J. T., Fausset, H., Miller, Z. T., Walk, S. T., Yeoman, C. J. (2023). Metabolic impact of polyphenol-rich aronia fruit juice mediated by inflammation status of gut microbiome donors in humanized mouse model. <em>Frontiers in Nutrition</em>, <em>10</em>. https://doi.org/10.3389/fnut.2023.1244692</li>
<li>Sinha, R., Clarke, J., Riethoven, J. (2018). Metabolic Syndrome, Gut Microbiome and Dietary Bioactive Peptides, an Unexplored Triad. <em>Diabesity</em>, <em>4</em>(1), 1. https://doi.org/10.15562/diabesity.2018.45</li>
<li>HAMZA, E., BRAHİM, O., KHALİD, S., CHAKİB, A. (2023). In vitro investigations of biological activities of Thymus willdenowii and Thymus atlanticus polyphenol-rich extracts. <em>International Journal of Secondary Metabolite</em>, <em>10</em>(1), 48-58. https://doi.org/10.21448/ijsm.1110715</li>
<li>Chen, X., Devaraj, S. (2018). Gut Microbiome in Obesity, Metabolic Syndrome, and Diabetes. <em>Current Diabetes Reports</em>, <em>18</em>(12). https://doi.org/10.1007/s11892-018-1104-3</li>
<li>Martin, D., Taheri, R., Brand, M., Draghi, A., Sylvester, F., Bolling, B. (2013). Polyphenol‐rich red and purple aronia berry extracts inhibit interleukin‐6 from mouse splenocytes.. <em>The FASEB Journal</em>, <em>27</em>(S1). https://doi.org/10.1096/fasebj.27.1_supplement.348.3</li>
<li>Dabke, K., Hendrick, G., Devkota, S. (2019). The gut microbiome and metabolic syndrome. <em>Journal of Clinical Investigation</em>, <em>129</em>(10), 4050-4057. https://doi.org/10.1172/jci129194</li>
<li>Divya, K. P., Hari, P., Kanwar, N., Aggarwal, N., Dhoat, P. S., Liu, L. (2023). The Role of the Gut Microbiome and the Hepatic Axis in the Pathogenesis of Metabolic Syndrome and Therapeutics. <em>Advanced Gut & Microbiome Research</em>, <em>2023</em>, 1-15. https://doi.org/10.1155/2023/5431615</li>
<li>Patrikios, I. (2020). Interplay between Gut Microbiome and Obesity: Insights from the Metabolic Syndrome, A Mini Review. <em>Biomedical Journal of Scientific & Technical Research</em>, <em>26</em>(2). https://doi.org/10.26717/bjstr.2020.26.004324</li>
<li>Unknown (2019). Acute Study of Anthocyanin-rich Bilberry and Polyphenol-rich Apple Extracts on Postprandial Glycaemic Response. <em>Case Medical Research</em>. https://doi.org/10.31525/ct1-nct04004182</li>
<li>A. Parnell, J., A. Reimer, R. (2012). Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome. <em>Gut Microbes</em>, <em>3</em>(1), 29-34. https://doi.org/10.4161/gmic.19246</li>
<li>Kahn, C. R., Ussar, S., Fujisaka, S. (2015). Interplay between genes and environment in insulin resistance and metabolic syndrome: the unique role of the gut microbiome. <em>Endocrine Abstracts</em>. https://doi.org/10.1530/endoabs.37.pl5</li>
<li>Kaliannan, K., Robertson, R. C., Murphy, K., Stanton, C., Kang, C., Wang, B. (2018). Estrogen-mediated gut microbiome alterations influence sexual dimorphism in metabolic syndrome in mice. <em>Microbiome</em>, <em>6</em>(1). https://doi.org/10.1186/s40168-018-0587-0</li>
<li>Pallister, T., Jackson, M. A., Martin, T. C., Zierer, J., Jennings, A., Mohney, R. P. (2017). Hippurate as a metabolomic marker of gut microbiome diversity: Modulation by diet and relationship to metabolic syndrome. <em>Scientific Reports</em>, <em>7</em>(1). https://doi.org/10.1038/s41598-017-13722-4</li>
<li>Ussar, S., Fujisaka, S., Kahn, C. R. (2016). Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome. <em>Molecular Metabolism</em>, <em>5</em>(9), 795-803. https://doi.org/10.1016/j.molmet.2016.07.004</li>
<li>Mannon, P. J., Chen, J., Pendergraft, A., Barnes, S., Mannon, R. B. (2022). 426.4: The Gut Microbiome Facilitates Metabolic Syndrome (MBS) Post Kidney Transplantation. <em>Transplantation</em>, <em>106</em>(9S), S490-S490. https://doi.org/10.1097/01.tp.0000888076.41051.cf</li>
<li>Parekh, P. J., Balart, L. A., Johnson, D. A. (2015). The Influence of the Gut Microbiome on Obesity, Metabolic Syndrome and Gastrointestinal Disease. <em>Clinical and Translational Gastroenterology</em>, <em>6</em>(6), e91. https://doi.org/10.1038/ctg.2015.16</li>
<li>Marasco, G., Cremon, C., Barbaro, M. R., Stanghellini, V., Barbara, G. (2022). Gut microbiota signatures and modulation in irritable bowel syndrome. <em>Microbiome Research Reports</em>. https://doi.org/10.20517/mrr.2021.12</li>
<li>Li, J., Lin, S., Vanhoutte, P. M., Woo, C. W., Xu, A. (2016). <i>Akkermansia Muciniphila</i> Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in <i>Apoe</i> <sup>−/−</sup> Mice. <em>Circulation</em>, <em>133</em>(24), 2434-2446. https://doi.org/10.1161/circulationaha.115.019645</li>
<li>Çatalkaya, G., Venema, K., Lucini, L., Rocchetti, G., Delmas, D., Daglia, M. (2020). Interaction of dietary polyphenols and gut microbiota: Microbial metabolism of polyphenols, influence on the gut microbiota, and implications on host health. <em>Food Frontiers</em>, <em>1</em>(2), 109-133. https://doi.org/10.1002/fft2.25</li>
<li>Pap, N., Fidelis, M., Azevedo, L., Carmo, M. A. V. d., Wang, D., Mocan, A. (2021). Berry polyphenols and human health: evidence of antioxidant, anti-inflammatory, microbiota modulation, and cell-protecting effects. <em>Current Opinion in Food Science</em>, <em>42</em>, 167-186. https://doi.org/10.1016/j.cofs.2021.06.003</li>
<li>Sun, C., Zhao, C., Çapanoğlu, E., Paoli, P., Simal‐Gándara, J., Ramkumar, K. M. (2020). Dietary polyphenols as antidiabetic agents: Advances and opportunities. <em>Food Frontiers</em>, <em>1</em>(1), 18-44. https://doi.org/10.1002/fft2.15</li>
<li>Chiva‐Blanch, G., Visioli, F. (2012). Polyphenols and health: Moving beyond antioxidants. <em>Journal of Berry Research</em>, <em>2</em>(2), 63-71. https://doi.org/10.3233/jbr-2012-028</li>
<li>Hul, M. V., Geurts, L., Plovier, H., Druart, C., Everard, A., Ståhlman, M. (2017). Reduced obesity, diabetes, and steatosis upon cinnamon and grape pomace are associated with changes in gut microbiota and markers of gut barrier. <em>American Journal of Physiology-Endocrinology and Metabolism</em>, <em>314</em>(4), E334-E352. https://doi.org/10.1152/ajpendo.00107.2017</li>
<li>Wei, X., Tao, J., Xiao, S., Jiang, S., Shang, E., Zhu, Z. (2018). Xiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota. <em>Scientific Reports</em>, <em>8</em>(1), 3685-3685. https://doi.org/10.1038/s41598-018-22094-2</li>
<li>Bié, J., Sepodes, B., Fernandes, P., Ribeiro, M. H. (2023). Polyphenols in Health and Disease: Gut Microbiota, Bioaccessibility, and Bioavailability. <em>Compounds</em>, <em>3</em>(1), 40-72. https://doi.org/10.3390/compounds3010005</li>
<li>Anhê, F. F., Nachbar, R. T., Varin, T., Vilela, V. R., Dudonné, S., Pilon, G. (2017). A polyphenol-rich cranberry extract reverses insulin resistance and hepatic steatosis independently of body weight loss. <em>Molecular Metabolism</em>, <em>6</em>(12), 1563-1573. https://doi.org/10.1016/j.molmet.2017.10.003</li>
</ol>
</article>